» Articles » PMID: 18083322

Motivational Enhancement Therapy to Improve Treatment Utilization and Outcome in Pregnant Substance Users

Overview
Specialty Psychiatry
Date 2007 Dec 18
PMID 18083322
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Pregnant substance users can benefit significantly from substance abuse treatment, but treatment retention can be challenging. Two hundred pregnant substance users entering outpatient substance abuse treatment at one of four treatment programs were randomized to receive either three individual sessions of Motivational Enhancement Therapy for pregnant substance users (MET-PS) or the first three individual sessions normally provided by the program. All participants were encouraged to participate in all other treatment offered by the program. Outcome measures included treatment utilization according to clinic records, qualitative urine toxicology measures, and self-report of substance use. One hundred sixty-two (81%) participants completed the 1-month active phase. Participants attended 62% of scheduled treatment on average and reported decreased substance use during the first month of treatment, with no differences between MET-PS and treatment-as-usual (TAU) participants. There was some evidence that the efficacy of MET-PS varied between sites and that MET-PS might be more beneficial than TAU in decreasing substance use in minority participants. These results suggest that MET-PS is not more effective than TAU for pregnant substance users in general but that there might be particular subgroups or treatment programs for which MET-PS might be more or less effective than TAU.

Citing Articles

Application of Causal Forest Model to Examine Treatment Effect Heterogeneity in Substance Use Disorder Psychosocial Treatments.

Susukida R, Amin-Esmaeili M, Badillo-Goicoechea E, Nguyen T, Stuart E, Rosenblum M Int J Methods Psychiatr Res. 2024; 34(1):e70011.

PMID: 39729473 PMC: 11675088. DOI: 10.1002/mpr.70011.


Predictors of urine toxicology and other biologic specimen missingness in randomized trials of substance use disorders.

Kelley A, Incze M, Baumgartner M, Campbell A, Nunes E, Scharfstein D Drug Alcohol Depend. 2024; 261:111368.

PMID: 38896944 PMC: 11405181. DOI: 10.1016/j.drugalcdep.2024.111368.


Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy.

Minozzi S, Ambrosi L, Saulle R, Uhm S, Terplan M, Sinclair J Cochrane Database Syst Rev. 2024; 4:CD015042.

PMID: 38682758 PMC: 11057221. DOI: 10.1002/14651858.CD015042.pub2.


Optimizing Contingency Management with Reinforcement Learning.

Kim Y, Brandt L, Cheung K, Nunes E, Roll J, Luo S medRxiv. 2024; .

PMID: 38585900 PMC: 10996730. DOI: 10.1101/2024.03.28.24305031.


Motivational interviewing for substance use reduction.

Schwenker R, Dietrich C, Hirpa S, Nothacker M, Smedslund G, Frese T Cochrane Database Syst Rev. 2023; 12:CD008063.

PMID: 38084817 PMC: 10714668. DOI: 10.1002/14651858.CD008063.pub3.


References
1.
Jones H, Svikis D, Tran G . Patient compliance and maternal/infant outcomes in pregnant drug-using women. Subst Use Misuse. 2002; 37(11):1411-22. DOI: 10.1081/ja-120014084. View

2.
Moyers T, Miller W, Hendrickson S . How does motivational interviewing work? Therapist interpersonal skill predicts client involvement within motivational interviewing sessions. J Consult Clin Psychol. 2005; 73(4):590-598. DOI: 10.1037/0022-006X.73.4.590. View

3.
Miller W, Yahne C, Tonigan J . Motivational interviewing in drug abuse services: a randomized trial. J Consult Clin Psychol. 2003; 71(4):754-63. DOI: 10.1037/0022-006x.71.4.754. View

4.
Shrout P, Fleiss J . Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979; 86(2):420-8. DOI: 10.1037//0033-2909.86.2.420. View

5.
SWANSON A, Pantalon M, Cohen K . Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. J Nerv Ment Dis. 1999; 187(10):630-5. DOI: 10.1097/00005053-199910000-00007. View